CD122 (IL-2/IL-15Rβ) is not targeted for killing. The engineered NK cells kill NY-ESO-1 peptide–HLA-A*02:01–positive tumor cells via the introduced TCR (and native NK cytotoxicity). IL-15 signals through CD122 to support NK survival/activation, not to kill CD122-expressing cells.